Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common type of dementia.
-
Alzheimer's disease (AD) is the most common form of dementia affecting millions of individuals, including family members who often take on the role as caregiver.
-
The hypocretins (Hcrts), also known as orexins, are two neuropeptides produced exclusively in the lateral hypothalamus.
-
41/100
Acetylcholinesterase (AchE), hydrolase enzyme, regulates the hydrolysis of acetylcholine neurotransmitter in the neurons.
-
When compared to patients prescribed donepezil, galantamine, or memantine, individuals prescribed rivastigmine were almost twice as likely to report dysphagia as an adverse event.
-
Two potential disease-modifying approaches for dementia are being vigorously tested: the early targeting of the neuropathology of Alzheimer's disease (AD) and multi-domain lifestyle interventions to promote resilience to neuropathology.
-
Given the unknown therapeutic value of targeting Alzheimer's disease pathology and the discovery of robust risk factors for dementia, non-pharmacological risk reduction (RR) is increasingly offered as an alternative to targeting Alzheimer's disease pathology.
-
Sleep plays an important role in homeostasis, brain plasticity, clearance of neurotoxins, cognition, memory, concentration, performance, and the regulation of the temperature, endocrine and immunological systems.
-
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions.
-
Sleep disorders are common in patients with Alzheimer's disease, and can even occur in patients with amnestic mild cognitive impairment, which appears before Alzheimer's disease.
-
Sedative antidepressants are commonly used drugs in the treatment of insomnia.
-
Drug repurposing aims to find new uses for already existing and approved drugs.
-
The effects of LRGT on animal models show significant benefits in AD pathology and cognitive impairment.
-
Experimental data reveal that lithium is capable of attenuating Alzheimer's disease pathology and stimulating adult hippocampal neurogenesis.
-
Alzheimer's disease (AD), is the most common type of dementia primarily affecting the later years of life.
-
41/100
Cognitive impairment risk in Parkinson's disease increases with disease progression and poses a significant burden to the patients, their families and society.
-
Insomnia is defined as difficulties of initiating and maintaining sleep, early awakening and poor subjective sleep quality despite adequate opportunity and circumstances for sleep with impairment of daytime performance.
-
One of the most frequent forms of dementia in neurological disorders is Alzheimer's disease (AD).
-
Lewy body dementia (LBD) is asynucleinopathy that results in clinical manifestation of motor and neuropsychiatric symptoms.
-
The aim of this work is to review tacrine analogues from the last three years, which were not included in the latest review work, donepezil and galantamine hybrids from 2015 and rivastigmine derivatives from 2014.
-
Polygala tenuifolia and its active components have multiplex neuroprotective potential associated with AD, such as anti-A β aggregation, anti-Tau protein, anti-inflammation, antioxidant, anti-neuronal apoptosis, enhancing central cholinergic system and promote neuronal proliferation.
-
Disease-modifying treatment strategies for Alzheimer disease (AD) are still under extensive research.
-
41/100
Consensus diagnostic criteria for MCI are available, making early recognition and accurate classification of MCI subtypes possible.
-
41/100
Development of disease-modifying treatments for Alzheimer's disease (AD) has been challenging, with no drugs approved to date.
-
Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the accumulation of amyloid β in the form of extracellular plaques and by intracellular neurofibrillary tangles, with eventual neurodegeneration and dementia.
From across this topic
9 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Drug repositioning for Alzheimer's disease
- Can we do better in developing new drugs for Alzheimer's disease?
- Anti-amyloid monoclonal antibody therapies in Alzheimer's disease - a scoping review
- Validation of 3- and 5-point severity scales to assess ARIA-E
- Therapy for Insomnia and Circadian Rhythm Disorder in Alzheimer Disease
- Anti-amyloid antibody therapies in Alzheimer's disease
- Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study
- Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials
- Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo